Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

NCT07128251 is registered in ClinicalTrials.gov with Anhui Provincial Hospital as lead sponsor.

NCT NCT07128251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07128251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Lead sponsor
Anhui Provincial Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 20, 2025
Completion date
December 30, 2029
Enrollment
47 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ctla-4, hepatocellular carcinoma (hcc), immunotherapy, pd-1, tace